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Abstract
Background: Activated B lymphocytes harbor programmed DNA double-strand breaks (DSBs) initiated by activation-
induced deaminase (AID) and repaired by non-homologous end-joining (NHEJ). While it has been proposed that these
DSBs during secondary antibody gene diversification are the primary source of chromosomal translocations in
germinal center (GC)-derived B cell lymphomas, this point has not been directly addressed due to the lack of
proper mouse models.
Methods: In the current study, we establish a unique mouse model by specifically deleting a NHEJ gene,
Xrcc4, and a cell cycle checkpoint gene, Trp53, in GC B cells, which results in the spontaneous development
of B cell lymphomas that possess features of GC B cells.
Results: We show that these NHEJ deficient lymphomas harbor translocations frequently targeting immunoglobulin
(Ig) loci. Furthermore, we found that Ig translocations were associated with distinct mechanisms, probably caused by
AID- or RAG-induced DSBs. Intriguingly, the AID-associated Ig loci translocations target either c-myc or Pvt-1 locus
whereas the partners of RAG-associated Ig translocations scattered randomly in the genome. Lastly, these NHEJ
deficient lymphomas harbor complicated genomes including segmental translocations and exhibit a high level of
ongoing DNA damage and clonal heterogeneity.
Conclusions: We propose that combined NHEJ and p53 defects may serve as an underlying mechanism for a high
level of genomic complexity and clonal heterogeneity in cancers.
Keywords: Non-homologous end-joining, Genomic instability, Chromosomal translocations, B cell lymphoma, Clonal
heterogeneity
Background
The occurrence of human B cell lymphomas is much
more frequent than that of T cell lymphomas [1]. This
phenomenon might be attributed to the multiple mecha-
nisms functioning in B lymphocytes that intrinsically
generate DNA double-stranded breaks (DSBs) or muta-
tions [2, 3]. Developing B cells in the bone marrow (BM)
undergo V(D)J recombination to assemble the variable (V)
region exons of Ig genes [4, 5]. V(D)J recombination
involves a cut-and-join mechanism initiated by the
lymphocyte-specific RAG1/2 endonucleases that recognize
and introduce DSBs at recombination signal sequences
(RSS) flanking germline V, D, and J segments [6]. Subse-
quently, broken V, D, and J segments are joined by ubiqui-
tous non-homologous end-joining (NHEJ) [7]. Ongoing
RAG-expression in newly generated B cells allows second-
ary V(D)J recombination, termed “receptor editing”, a
process in which additional Ig gene rearrangements may
occur in BM immature B cells [8–12]. Ultimately, RAG
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down-regulation in mature B cells prohibits further V(D)J
rearrangement [13, 14]. However, our previous studies
suggest that mature B cells may also undergo secondary
V(D)J recombination at low frequency in an in vitro cul-
ture system [15]. While RAG contributes to the genomic
instability of developing B cells [16–18], its role in mature
B cell lymphomagenesis is still under debate.
Upon antigen activation, mature B cells undergo further
genetic diversification processes, namely, class switch
recombination (CSR) and somatic hypermutation (SHM),
in specialized secondary lymphoid structures termed
germinal centers (GCs) [19–22]. Activation-induced
deaminase (AID) initiates CSR and SHM [23, 24], which
deaminates cytosines in transcribed DNA and ultimately
causes DSBs or point mutations [25–28]. CSR is a region-
specific deletional recombination process required for
producing isotype-switched antibody such as IgG [29].
AID-initiated DSBs occur at the switch (S) regions within
the Igh locus, which are eventually resolved as deletions in
cis on the same chromosomes, thereby causing the switch
of constant regions of Igh [29]. SHM introduces predom-
inantly point mutations into IgH and IgL V region exons,
allowing the selection of B cell clones with increased affin-
ity for antigen [27]. Besides Ig loci, AID can target
non-Ig loci to induce genetic lesions, thereby posing
a threat to genome stability [30]. Consistently, the dysreg-
ulated AID activity contributes to tumorigenesis [31, 32].
We and others have shown that AID is required for gener-
ating chromosomal breaks at the Igh locus [15] and the
Igh-c-myc translocations [33].
Apart from programmed DSBs, B lymphocytes harbor
general DSBs arising from genotoxic agents such as
oxidative damage or DNA replication errors. To pre-
serve genome integrity, two major DSB repair pathways
operate in mammalian cells: homologous recombination
(HR) and NHEJ. While HR-directed repair requires
homologous templates, NHEJ can repair DSBs with little
or no sequence homology [34]. The NHEJ pathway joins
programmed DSBs in lymphocytes including RAG- or
AID-initiated DSBs [35] and repairs general DSBs in all
types of cells [34]. The NHEJ pathway includes Ku70,
Ku80, DNA-PKcs, XLF, Artemis, XRCC4, and DNA
Ligase 4 (Lig4) [34]. XRCC4, Lig4, and possibly XLF
form a complex to catalyze the end-ligation step of
NHEJ [34, 36]. Germline deletion of NHEJ results in
severe combined immune deficiency due to inability to
complete V(D)J recombination [4, 7]. Conditional deletion
of Xrcc4 or Lig4 in peripheral B cells reduces the CSR level
and causes a high level of chromosomal breaks and trans-
locations at the Igh locus due to inability to repair AID-
initiated DSBs [15, 37]. While defective DSB repair leads
to genomic instability, cell cycle checkpoints can
protect organisms from adverse downstream effects,
such as transformation, by eliminating damaged cells.
As DSB repair and checkpoint mechanisms comple-
ment each other, loss of both can cause dramatic pre-
disposition to transformation in mouse lymphocytes,
often leading to lymphomas due to the inappropriate
repair of programmed or general DSBs [38]. For
instance, deficiency of Xrcc4, Lig4, and Xrcc6 (Ku70) in
conjunction with Trp53 deficiency causes pro-B cell
lymphomas carrying co-amplified Igh-c-myc loci [39–43].
TP53 is a well-known tumor suppressor gene, which
encodes p53 protein capable of responding to diverse
cellular stresses by regulating the expression of its target
genes, thereby inducing cell cycle arrest, apoptosis, or
senescence, modulating DNA repair or metabolism and
serving as the guardian of the genome [44–46].
We previously showed that conditionally deleting Xrcc4
in Trp53-deficient peripheral B cells resulted in the devel-
opment of surface Ig negative lymphomas from editing
and switching B cells (termed CXP lymphomas) [47].
Although CXP tumors have mature B cell characteristics,
they appear to be very different from human mature B cell
lymphomas. For instance, CXP lymphomas do not express
IgH or IgL chain protein on the surface or intracellularly
and show no SHM in the rearranged VDJ exon [47]. In
contrast, most of human mature B cell lymphomas are
surface Ig positive except classical Hodgkin’s lymphoma
and a few others [1]. These differences suggest that the
mechanism of lymphomagenesis and the developmental
stage of tumor progenitors are very different between
CXP and human mature B cell lymphomas. Such differ-
ence may be due to the relatively early deletion of Xrcc4
via CD21cre. CD21 begins to be expressed between the
immature and the mature B cell stages, specifically in
transitional B cells [48]. Thus, in mice performing
CD21cre-mediated Xrcc4 deletion, it is likely that
some DSBs are generated before the cells are recruited
into the GC reaction. In the current study, we delete Xrcc4
and Trp53 at a later stage of mature B cell development
during the GC reaction, which leads to B cell lymphomas
that possess GC B cell features and harbor frequent Ig loci
translocations, ongoing DNA damage and a high level of
clonal heterogeneity.
Results
Deletion of Xrcc4 but not Trp53 via Cγ1cre leads to a high
level of genomic instability at the Igh locus
We established a new mouse model in which Xrcc4 (X)
and Trp53 (P) genes were deleted at a later stage of
mature B cell development using Cγ1Cre [49]. In
Cγ1Cre knock-in mice, Cre expression is driven by the
endogenous Iγ1 promoter and occurs in the majority of
GC B cells [49]. Consistently, we found that GC B cells
have the complete deletion of Xrcc4 (X) floxed allele
in Cγ1Cre/Xc/+ mice (c: floxed allele; +: wt allele)
(Additional file 1: Figure S1A). Then, we examined
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whether deletion of Xrcc4 or Trp53 via Cγ1cre led to a
high level of genomic instability in primary B cells. To do
so, we assayed for Igh locus-specific genomic instability in
B cells that can be induced via anti-CD40/IL4 activation
in the in vitro culture of primary B cells [15, 37]. Using
metaphase fluorescence in situ hybridization (FISH), we
found that anti-CD40/IL4-stimulated Xrcc4/Trp53-
double deficient (DKO) B cells harbored a high level of
Igh locus instabilities, including breaks and transloca-
tions (Fig. 1a, b). Furthermore, our data showed that
Xrcc4 deficiency alone resulted in a high level of Igh
locus genomic instability; in contrast, Trp53 deficiency
did not enhance the level of genomic instability in
activated B cells compared to wt controls (Fig. 1a).
Thus, the Igh locus genomic instability in the DKO B





































Fig. 1 Deletion of Xrcc4 but not Trp53 via Cγ1cre leads to a high level of genomic instability at the Igh locus. a Quantification of Igh abnormalities
in day 4 anti-CD40/IL4-activated wt (n = 6), Cγ1-p53c/c (n = 4), Cγ1-X4c/c (n = 3), and DKO (n = 6) splenic B cells. Data are presented as mean ± s.e.m.
Statistical analyses were calculated by a Student’s t test with two-tailed distribution and equal variance. p = 0.024 (control vs Cγ1-p53c/c), p = 6.78E-05
(control vs Cγ1-X4c/c), p = 1.03E-06 (control vs DKO), p = 0.805 (Cγ1-X4c/c vs DKO). b Top: Diagram of Igh metaphase FISH probes and abnormalities.
An intact Igh shows co-localized red and green signals while a broken locus appears as split red and green signals. Bottom: Example of metaphase FISH
showing Igh breaks indicated with white arrows
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Combined deletion of Xrcc4 and Trp53 via Cγ1cre
predisposes B cells to lymphomagenesis
We conducted cohort studies by monitoring two cohorts
of Cγ1CreXcPc mice for the occurrence of B cell lymph-
omas (Xc: Xc/c or Xc/−; Pc: Pc/c or Pc/−). Within the first
cohort, we found that Cγ1CreXcPc/+ mice (Additional file
1: Figure S1B, n = 19, blue line) survived normally and
were not cancer-prone. This phenotype is similar to that
of CD21CreXc/- mice [47] in that both lines only have
Xrcc4, but not Trp53, deleted. Cγ1CreXc/+Pc mice
(Additional file 1: Figure S1B, n = 20, green line), which
still express XRCC4, developed thymic lymphomas or
solid tumors. This phenotype is likely due to p53 haploin-
sufficiency as the genotypes of all the tumors are Pc/−. In
contrast, 11 out of 47 Cγ1CreXcPc mice succumbed to B
lineage lymphoma (Additional file 1: Figure S1B, n = 47,
red line) as all 11 tumors expressed B lineage markers in-
cluding B220 and CD19, while the rest of morbid mice
died of thymic lymphomas or solid tumors. The floxed
Xrcc4 allele was deleted in all of the B lineage lymphomas
but not in thymic lymphomas and solid tumors (data not
shown). Within the second cohort, we observed a survival
curve closely resembling the first one, with a similar pene-
trance and latency for tumor development (Fig. 2a), albeit
the second cohort included only wt controls (n = 37) and
Cγ1CreXcPc mice (n = 51). We termed the Cγ1CreXcPc-de-
rived B lineage tumors G1XP lymphomas.
Phenotypic characterization of G1XP lymphomas
We performed Southern blotting to assay G1XP tumor
DNA for Igh rearrangements and found that 7 out of 11
analyzable primary G1XP tumors from the first cohort
exhibited clonal Igh rearrangements, along with varying
degrees of a germline JH band (Additional file 1:
Figure S1C). However, the germline band usually oc-
curred in low levels indicating derivation from non-B
lineage cells within the tumor. Consistently, the tumor
samples analyzed from the second cohort also displayed
clonal rearrangements of the JH allele (Fig. 2b). Histo-
logical analysis of the tumor samples showed that the
lymphoma cells possessed diffusely enlarged cytoplasm,
salient nuclei, and nucleoli (Fig. 2c), consistent with
immunoblastic B cells. Phenotypic characterization of
G1XP lymphomas was performed by flow cytometry
(Additional file 1: Table S1). We found that all of the
lymphoma samples consistently expressed B220, CD24,
CD38, CD43, CD93, and CD138. The majority of
lymphomas also expressed PNA, a marker for GC B
cells (see below), and about 40 % of them were sur-
face IgG positive (Additional file 1: Table S1).
To test whether G1XP lymphomas derived from B
cells that had undergone SHM/CSR, we cloned the
VDJH exons from three G1XP lymphomas using a PCR
approach [47]. We found that G1XP tumors contained
structurally normal in-frame or out-of-frame V(D)J rear-
rangements; more importantly, we sequenced these VDJH
exons and downstream JH introns and found that these
three tumors harbored 13, 1, and 3 mutations, respect-
ively, in the JH regions (Additional file 1: Figure S2). These
results further confirm that inactivation of Xrcc4 and
Trp53 via Cγ1cre leads to B cell lymphomas capable of
Fig. 2 Establishment of the G1XP B cell lymphoma model.
a Kaplan-Meier survival curve: percent survival of wt controls
(n = 37) and Cγ1CreXcPc mice (n = 51) vs age in days is shown.
b Southern Blot analysis of second cohort of Cγ1CreXcPc mice for
JH rearrangements. G1XP lymphoma genomic DNA was employed for
EcoRI digestion and hybridized with the JH4 probe. Germline (GL)
bands are indicated (arrow heads). MLN stands for mesenteric
lymph node. c H&E analysis of G1XP lymphomas. Left: a high
level of apoptotic cells (red arrows) (objective ×40); Right: diffusely
enlarged nuclei (red arrow, bottom) and salient nucleoli (red arrow, top)
(objective ×63). Scale bars 50 μm
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undergoing SHM. Thus, we conclude that the deletion of
both Xrcc4 and Trp53 genes via Cγ1Cre results in the
development of novel B cell lymphomas.
Analysis of Ig loci translocation junctions identifies known
and novel translocation partners
We performed whole genome next generation sequen-
cing (NGS) to identify the inter-chromosomal transloca-
tions (CTX) involving Ig loci in 6 G1XP lymphomas.
NGS allows us to molecularly characterize the CTX
junctions at the base pair (bp) level, which may provide
insights into the molecular mechanisms leading to these
translocations. NGS identified 25 CTXs involving Ig
genes, 20 of which were confirmed by manual alignment
to reference databases (mm9), while the remainder was
excluded due to alignment artifacts or sequencing limita-
tions. Among the 20 CTXs, 16 of them occurred at the Igh
locus, with 10 breakpoints present within or around S re-
gions on chromosome 12q13.2 (Fig. 3a, Additional file 1:
Table S2), indicating that the translocations originated
from CSR process; the other 6 CTXs occurred in close
proximity to various VH gene segments of the Igh locus
(Fig. 3a, Additional file 1: Table S2), suggesting that these
CTXs were mediated by RAGs. The additional 4 CTXs tar-
geted Igκ or Igλ loci on chromosome 6 or 16, respectively,
with the breakpoints occurring in close proximity to Vλ or
Vκ gene segments, consistent with RAG-mediated DSBs
(Fig. 3a, Additional file 1: Table S2).
Notably, an interesting pattern emerged among these
CTXs that apparently separated into two categories.
First, all of the 10 CTXs occurring around S or C
regions of the Igh locus were translocated to the c-myc
or plasmacytoma variant translocation 1 (Pvt1) locus on
chromosome 15 (8 vs 2, respectively) (Fig. 3a). The
translocation breakpoints at the c-myc locus clustered in
the 5′ non-coding regions on chromosome 15qD1
(Fig. 3b, Additional file 1: Table S2). Second, all of the
10 CTXs occurring close to V gene segments of Igh, Igκ,
and Igλ were translocated to various chromosomes
involving random genetic or intergenic regions (Fig. 3a)
(Additional file 1: Table S2). This intriguing pattern of
translocation partners suggests that distinct mechanisms
operate to mediate these two categories of transloca-
tions, probably involving AID vs RAGs, respectively.
NGS data revealed a novel translocation partner of Igh
locus, which targeted the Pvt1 locus (Fig. 3c), located
about 30 kb telomeric of the c-myc locus. The Pvt1
locus contains a long non-coding RNA gene, which is
a frequent translocation partner in mouse plasmacyto-
mas and variants of human Burkitt’s lymphomas (BL)
[50, 51]. NGS data identified Igh breakpoints located
within Sμ or Sα regions, strongly implicating the involve-
ment of AID (Fig. 3d). The junctional sequences harbored
micro-homology (MH), an indicator of alternative end-
joining (A-EJ) [35, 52]. Taken together, our data suggest
that Ig loci translocations are likely caused by AID or
RAG activity.
Apart from CTX junctions, we also identified V(D)J re-
combination junctions from our NGS data. Since Xrcc4
was deleted in the GC B cells, these lymphoma cells har-
bored normal D-J or V-D-J recombination junctions at
the Igh locus (Additional file 1: Figure S3, junction 1
and 2, respectively). In contrast, we detected aberrant
Igλ locus V-J rearrangements, which harbored large
deletions of Vλ1 or Jλ3 exon including 41 bp of Vλ1 exon
and the entire Jλ3 exon (Additional file 1: Figure S3, junc-
tion 3). These data are consistent with our previous results
showing that CD21cre-mediated Xrcc4 deletion led to ab-
errant Igλ rearrangements [15, 47]. We identified MH at
the V-J junction (Additional file 1: Figure S3, junction 3),
consistent with the involvement of A-EJ. Taken together,
our data suggest that these aberrant Igλ rearrangements
occurred in the absence of Xrcc4, probably in the context
of secondary V(D)J recombination.
Validation of clonal translocations involving Ig loci in
G1XP lymphomas
To further validate the observed genomic instability, we
performed metaphase FISH assay to detect locus-specific
clonal translocations, which were also validated via inde-
pendent methods (Additional file 1: Table S3). Of note,
all of the detailed analysis utilized the tumor samples
from the second cohort of Cγ1CreXcPc mice. Among the
six tumors sequenced by NGS, we confirmed that four
out of six samples harbored clonal c-myc translocations
while five out of six had Igh locus translocation (Fig. 4a).
Clonal translocations were defined as more than 80 % of
tumor metaphases harboring such translocations. Fur-
thermore, we found that six out of nine analyzed G1XP
lymphoma samples harbored clonal c-myc translocations
while seven out of nine contained clonal Igh transloca-
tions. Next, we performed FISH analysis using 3′Igh
(red) and 3′c-myc (green) probes or 5′c-myc (red) and
5′Igh probes (green) to determine whether these are re-
ciprocal translocations occurring between Igh and c-myc
loci. Indeed, we found that Igh and c-myc probes were
juxtaposed on the translocated chromosomes (Fig. 4b).
Thus, we conclude that the majority of G1XP lymph-
omas harbor Igh-c-myc reciprocal translocations. In
addition to these translocations, we detected clonal
translocations involving the Igλ locus (Additional file 1:
Figure S4), one of the Ig light chain gene loci, in the
majority of G1XP lymphomas analyzed.
Interestingly, we identified a clonal Igh translocation in
one G1XP lymphoma that did not involve c-myc locus
since c-myc FISH probes had intact signals (Fig. 4c).
Notably, this particular G1XP lymphoma (119 J) is aneu-
ploid as evidenced by five copies of broken Igh locus
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Fig. 3 (See legend on next page.)
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and five copies of intact c-myc locus (Fig. 4c), suggesting
the existence of novel translocation partners. Indeed,
NGS data showed that this particular lymphoma
harbored an Igh-Pvt1 translocation (Fig. 3d). Next, we
performed FISH analysis to validate the occurrence of
this translocation. Surprisingly, we found that almost all
metaphases harbored an intact Pvt1 locus with 5′ and 3′
Pvt1 probes always co-localized (Fig. 5a, left panel, and 5b),
suggesting the absence of gross chromosomal structural
alterations at the Pvt1 locus. To reconcile the apparent
discrepancy between NGS and FISH data, we used the 3′
Igh and 3′Pvt1 probes for FISH assay and found that these
two probes co-localized in 100 % of metaphases analyzed
(Fig. 5a, middle panel and 5b). In contrast, the 5′Igh
and 5′Pvt1 probes were not co-localized (Fig. 5a, right
panel, and 5b). Thus, these data demonstrated that a
piece of chromosome 12 was inserted into the Pvt1
locus, which contained the centromeric portion of the
Igh locus encompassing the region from Sα to Sμ
(Fig. 5c). More importantly, these data implicate that
G1XP lymphomas harbor complicated genomes in-
cluding segmental translocations.
G1XP lymphomas harbor ongoing DNA damage and a
high level of clonal heterogeneity
We hypothesize that G1XP lymphomas probably harbor
ongoing genomic instability that mediates the acquisi-
tion of chromosomal structural rearrangements. To test
this hypothesis, we examined the DNA damage level in
G1XP lymphomas via detecting the phosphorylation of
H2AX (at Ser 139), a variant of H2A. H2AX phosphoryl-
ation occurs at sites flanking DSBs minutes after their
induction, leading to the formation of distinct gamma-
H2AX foci (γ-H2AX) [53]. Thus, γ-H2AX foci reflect
the level of ongoing DSBs and are often used as an indi-
cator of DSB formation. We used a flow cytometry-
based method to measure γ-H2AX level in the G1XP
lymphomas and in wt naïve (B220+PNAlow) and GC
(B220+PNAhigh) B cells as controls. Our data showed
that G1XP lymphoma cells displayed a remarkably high
level of γ-H2AX staining (Fig. 6a, right panel). In
addition, this particular lymphoma expressed the GC B
cell marker, PNA (Fig. 6a, left panel). In contrast, both
the wt naïve and GC B cells exhibited a minimal level of
γ-H2AX staining (Fig. 6b). Notably, the γ-H2AX level is
consistently higher in GC B cells than naïve B cells
(Fig. 6b). Thus, we conclude that G1XP lymphomas
harbor ongoing DNA damage.
We predict that G1XP lymphomas may display a
higher level of clonal heterogeneity. To test this possibility,
we employed FISH assays to further analyze the lymph-
omas harboring the c-myc translocation in detail. Our
analysis of these lymphomas showed that all metaphases
indeed contained a c-myc translocation as shown by the
split signals of 5′ and 3′ c-myc probes. Unexpectedly, we
found that the configuration of FISH signals was highly
heterogeneous since we observed an array of configura-
tions that showed various numbers of intact, green (G)
only or red (R) only FISH signals (Fig. 7a). It appeared that
there were a few dominant subclones, for example, clone
(1,3,2) and clone (2,2,2) (intact, G only, R only) (Fig. 7b),
which occurred at a relatively high frequency, and many
minor subclones carried various configurations of FISH
signals (Fig. 7a). Thus, our G1XP lymphomas may provide
a unique and novel model to study the mechanism of
ongoing genomic instability and clonal heterogeneity.
Discussion
A high level of genomic complexity and clonal hetero-
geneity may contribute to relapse or therapy resistance
[54, 55]; however, key determinants regulating their
generation have not been clearly addressed. In the
current study, we establish a unique lymphoma model
by specifically deleting Xrcc4 and Trp53 in the subset of
B cells proposed to be prone to lymphomagenesis,
namely, GC B cells [1]. Our mutant mouse B cells
spontaneously develop B cell lymphomas, and we
employed multiple approaches to characterize their gen-
omic instability. Our studies reveal several important
discoveries: (1) Ig loci translocations can be attributed
to distinct mechanisms including AID- or RAG-
associated DSBs in mature B cells; (2) AID-associated
Igh translocations target oncogenes such as c-myc
whereas RAG-associated translocations appear to involve
random genomic loci; and (3) G1XP lymphomas harbor
complicated genomes including segmental translocations,
and exhibit a high level of ongoing DNA damage and
clonal heterogeneity. Taken together, we propose that
(See figure on previous page.)
Fig. 3 Analysis of CTX junctions identifies known and novel translocation partners. a A Circos plot depicts all CTXs involving Igh, Igκ, and Igλ loci.
Individual chromosomes are shown as color-coded bars with specific banding patterns. The region on chr12 (in green) (114,480,000–117,249,000)
is zoomed in ×400 including the Igh locus while the region on chr15 (in blue) (61,800,000–62,083,000) is zoomed in ×1600 including c-myc and
Pvt1 loci. All Igh CTXs involving S or C regions are translocated to c-myc or Pvt1 locus shown as a cluster of blue lines. All other Ig CTXs involving
V gene segments are translocated to various chromosomes shown as different color-coded lines. b The view within the IGV browser shows all the
CTX breakpoints occurring upstream of or within c-myc 1st exon. c The location of Pvt1 translocations shown in the IGV browser. d Analysis of
junction sequences of the Igh-Pvt1 translocation. Sequences from NGS are aligned with genomic sequences of mm9 with chr15 sequence in black
and chr12 sequence in blue. Micro-homology at the junctions is in red and underlined
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combined NHEJ and p53 defects may serve as an under-
lying mechanism for a high level of genomic complexity
and clonal heterogeneity in cancers.
The NHEJ and p53 deficiency models have made
significant contributions to our understanding of trans-
location and lymphomagenesis, more importantly, the
molecular mechanism of DNA repair [15, 37, 39–43, 47].
Emerging evidence suggests that defects in DSB repair can
lead to oncogenic genomic instability and, in support of
this notion, mutations in DNA break repair factors
are implicated in a number of human tumors, includ-
ing breast, colon, and lung cancers [56]. In addition,
somatic mutations in NHEJ factors have been identi-
fied in different types of human tumors including
hypomorphic mutations of Artemis in EBV-associated
lymphomas [57], mutations of Lig4 or XLF associated
with non-Hodgkin’s diffuse large B cell lymphoma
[58–60], and mutations of DNA-PKcs in glioblastoma
and lung cancer [56]. TP53 mutations were associated
with human BL, its leukemic counterpart L3-type B
cell acute lymphoblastic leukemia, B cell chronic
lymphocytic leukemia (CLL), and, in particular, its
stage of progression known as Richter’s transformation
[61]. Richter syndrome (RS) is characterized by the trans-
formation of CLL to high-grade non-Hodgkin’s lymph-
oma. Consistently, a recent study by performing a
comprehensive molecular characterization of 86 patho-
logically proven RS reveals that TP53 disruption (47.1 %)
and c-myc abnormalities (26.2 %) were the most frequent
alterations in RS [62], both of which are present in our
models. Therefore, it is likely that defects in both NHEJ
and p53 or in the modulators of these pathways may
contribute to the development of human lymphomas, at
least, a subset of them.
Our NGS data identified Igh translocation partners,
c-myc and Pvt-1, which are often observed in BL and a
subset of diffuse large B cell lymphomas [51, 63–67].
Thus, our model might provide a unique platform to bet-
ter elucidate the molecular mechanisms of translocations
in B cell lymphomagenesis. Prior studies demonstrate an
important role of AID in promoting translocations in B
cells [30]. We and others also prove that the NHEJ
deficiency-induced Igh locus instability [15] or the gener-
ation of Igh-c-myc translocation is completely dependent
on AID [68]. Consistently, we found that the majority of
Igh translocations in G1XP lymphomas probably origi-
nated from AID-initiated DSBs, further solidifying its role
in inducing Igh locus genomic instability. Furthermore, we
find that half of Ig translocations occur in close proximity
to V gene segments in the Igh, Igκ, or Igλ locus, strongly
implicating these translocations catalyzed by RAGs.
Notably, the partners of these Ig V gene translocations are
random genetic loci or intergenic regions scattered all
over the genome. We suggest that the generation of such
translocations probably is largely influenced by mechanis-
tic factors [69], such as the increased frequency of RAG-
mediated DSBs at the Igh or Igl locus in the context of
Fig. 4 FISH validation of Igh locus translocations. a, b Inactivation of
Xrcc4 and Trp53 via Cγ1-cre leads to reciprocal Igh-c-myc translocation
in G1XP lymphoma (46 J). a Upper left: Diagram of Igh FISH probes.
Bottom left: An example of metaphase Igh FISH image. An intact Igh
shows co-localized red and green signals while a translocated locus
appears as split red and green signals on different chromosomes (white
arrow). Upper right: Diagram of c-myc FISH probes. Bottom right: An
example of metaphase FISH showing c-myc locus translocation (yellow
arrow) and an intact c-myc locus. b Left: A metaphase FISH image
showing the t(12;15) translocation with 3′Igh (red) and 3′c-myc (green)
probes juxtaposed on the derivative chr12 (white arrow). Right: A
metaphase FISH image showing the t(15;12) translocation with 5′c-myc
(red) and 5′Igh (green) probes juxtaposed on the derivative chr15
(yellow arrow). A normal chr12 and chr15 are also present in the
metaphase. c Left: a metaphase FISH image showing the Igh locus
translocations in G1XP lymphoma (119 J) with 3′ and 5′Igh probes split.
Right: a metaphase FISH image showing the intact c-myc locus with
3′ and 5′ probes co-localized in the same lymphoma sample
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secondary V(D)J recombination. In this regard, these re-
sults are consistent with our previous findings that a small
percentage of peripheral B cells harbor RAG-dependent
Igλ breaks/translocations in the absence of Xrcc4 [15].
Thus, our conclusion is further corroborated that
mature B lymphocytes can undergo secondary V(D)J
recombination, which may contribute to mature B cell
lymphomagenesis.
Our data reveal that Trp53 deficiency is essential
to cause B cell lymphomas; however, Trp53 deficiency
per se does not increase the level of DSBs markedly.
Thus, we propose that Trp53 deficiency enhances the
tolerance threshold of B cells for genomic instability
induced by DNA repair deficiency in our model,
thereby predisposing to lymphomagenesis. Consistent
with our hypothesis, it has been shown that, in re-
sponse to DSBs, p53 is phosphorylated and activated
by ATM [70], then monitors DSBs in the context of
G1 checkpoints, and signals arrest and/or apoptosis
[71]. Trp53 deficient mice usually succumb to thymic
lymphomas that are aneuploid but lack translocations
[72–75]. Of note, CD21cre-mediated deletion of Trp53 in
peripheral B cells results in the development of mature B
cell lymphomas (IgM+) that lack recurrent clonal
translocations involving Ig or c-myc loci [76]. Overall,
these findings support our hypothesis that Trp53 defi-
ciency enables B cells to tolerate genomic instability.
Furthermore, we propose that the regulation of
genomic instability tolerance is more p53-dependent
in B cells than in other cell lineages. This notion is
supported by the findings that NHEJ/p53 germline
deficient mice developed only pro-B cell lymphomas
[39, 43]. Thus, our unique mouse model may facili-
tate the discovery of critical components of p53-
mediated effector cascades that regulate genomic
instability tolerance. Furthermore, we were able to
establish cell lines from our lymphoma model (data
not shown), which would facilitate subsequent studies.
Addressing these fundamental questions potentially
identifies targets that specifically attack cancer cells
with unstable genomes, while leaving genetically
stable normal cells unaffected.
Fig. 5 G1XP lymphomas harbor segmental translocations involving Pvt1 locus. a Metaphase FISH analysis of the Igh-Pvt1 translocation in G1XP
lymphoma (119 J). Top: Diagrams of Igh or Pvt1 FISH probes. Bottom left: five copies of the 5′ (green) and 3′ (red) Pvt1 probes are co-localized
(yellow arrows); Bottom middle: three copies of the 3′Igh (green) and 3′Pvt1 probes are co-localized (white arrows); Bottom right: five copies of
5′Pvt1 probe (green) and two copies of 5′ Igh probe (red) are not co-localized (indicated by green or red arrows, respectively). b Quantification of
Igh-Pvt1 translocations analysis in G1XP lymphoma (119 J). The number of analyzed metaphases is indicated. c Schematic map of t(15;12;15)
translocation in G1XP 119 J. Chr15 is in red and the Pvt1 locus is depicted in blue line with the 5′ and 3′ flanking FISH probes indicated. The
inserted region of Chr12 is in green encompassing the region from Sα (junction 2) to Sμ (junction 1) as shown in Fig. 3d. The breakpoints of Pvt1
locus are adjacent to each other in these two CTX junctions with only 143 bp deleted in the Pvt1 locus
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With regard to the potential of our model in clinical ap-
plications, such as biomarkers for diagnosis and therapy
[77], we suggest that our unique model might potentially
provide novel insights into the biomarker development in
predicting the onset of the B cell lymphomas, given that
this lymphoma model has a relatively long latency and
low penetrance. In addition, novel therapies have been
developed rapidly to treat B cell lymphomas or CLL, for
example, Ibrutinib and new agents are effective for TP53
mutant lymphoma cells; thus, there is the potential of
clinical applications of our lymphoma model for testing
new agents [78–80]. Mechanistically, it would be of inter-
est to elucidate which signaling pathway is required for
the survival of these lymphoma cells.
Conclusions
Deletion of Xrcc4 and Trp53 via Cγ1Cre leads to novel
B cell lymphomas that appear to derive from GC B cells.
These B cell lymphomas harbor ongoing DNA damage
and exhibit a high level of clonal heterogeneity for
characteristic c-myc translocations. We propose that
combined NHEJ and p53 defects may serve as an under-
lying mechanism for a high level of genomic complexity
and clonal heterogeneity in cancers.
Methods
Generation of mouse models
Cγ1Cre knock-in (KI) mice [49], Xrcc4 [37], or Trp53
[81] conditional knock-out (KO) mice were generated
previously. These mice were in mixed genetic back-
ground of C57BL/6, 129/Ola, and FVB/N [37, 49, 81].
Animal work was approved by the Institutional Animal
Care and Use Committee of University of Colorado
Anschutz Medical Campus (Aurora, CO), National
Jewish Health (Denver, CO), and Children’s Hospital in
Boston (Boston, MA).
B cell culture, FISH, and Southern Blot analysis
Splenic B cells were isolated from naïve mice, purified
by negative selection kit (Stem Cell Technologies,
Canada), activated with anti-CD40 and IL4 as described
previously [82], and collected 4 days after culture for
metaphase preparation and FISH analysis. FISH analysis
was performed with specific BAC probes as previously
described [82] (see details in Additional file 1). Genomic
DNA was isolated from tumor masses or normal tissues
from control mice, and Southern blotting was performed
as previously described [41].
Fig. 6 G1XP lymphomas harbor ongoing DNA damage. a FACS analysis of a GC B cell marker, PNA (left panel) and γ-H2AX foci staining (right panel)
for G1XP lymphomas (n = 3 per group). b Wt splenocytes were isolated from immunized mice and stained for GC B cell markers, B220 and PNA. The
level of γ-H2AX foci staining was shown for naïve B cells (B220+PNAlow) and GC B cells (B220+PNAhigh). Representative FACS plots are shown from three
independent experiments using independent tumor samples
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H&E staining, flow cytometry, and H2AX foci staining
Tumor masses usually presented in the abdomen and
were adjacent to gut-associated lymphoid tissues such as
mesenteric lymph nodes or Peyer’s patch. Tumors were
dissected, fixed in 10 % formalin, and processed for
H&E histology staining. Tumor single-cell suspensions
were prepared and subjected to flow cytometry for
phenotypic characterization. Samples were analyzed
using a FACSCalibur (BD Bioscience), and FACS analysis
was performed with FlowJo software. Single-cell suspen-
sions prepared from tumors or wt naïve or GC B cells
were stained for γ-H2AX foci according to the manufac-
turer’s instructions (BD Bioscience). The generation of
splenic GC B cells was induced by in vivo immunization
as described previously [82].
NGS library preparation, sequencing platform, and data
analysis
Tumor DNA samples were employed to generate the
NGS paired-end library using the standard TruSeq DNA
library preparation kit (Illumina, San Diego, CA). The
libraries were subjected to whole genome sequencing on
the Illumina Hi-Seq 2000 platform (pair-ended, 2 × 100 bp
per read). Details of NGS analysis are provided in the
Additional file 1 including usage of CREST software [83]
and generation of Circos plots [84].
Additional files
Additional file 1: Figure S1. Establishment of G1XP lymphoma
model. (A) Specific Xrcc4 deletion via Cγ1Cre in GC B cells. PCR analysis
of genomic DNA isolated from bone marrow (BM), thymus, sorted naïve
B cells (B220+PNAlow), and GC B cells (B220+PNAhigh) of immunized
Cγ1Cre KI or Cγ1CreXc/+ mice. The middle band is non-specific amplifica-
tion of PCR reaction for BM, thymus and B220+PNAlow B cells. GC B cells
(B220+PNAhigh) show the complete deletion of Xrcc4 floxed allele. Sple-
nocytes were stained using anti-B220 and anti-PNA antibodies. (B) Kaplan
Meier survival curve of the first cohort of mice including Cγ1CreXcPc/
+mice (n=19, blue line), Cγ1CreXc/+Pc mice (n=20, green line) and
Cγ1CreXcPc mice (n=47, red line). (C) Southern Blot analysis of 1st cohort
of Cγ1CreXcPc mice. G1XP lymphomas harbor clonal JH rearrangements.
Southern blot analyses for JH rearrangements in G1XP lymphoma gen-
omic DNA employing EcoRI digestion and the JH4 probe. Germline (GL)
bands are indicated (arrow heads). Asterisks (*) indicate rearranged JH
locus in lymphoma DNA. MLN stands for mesenteric lymph node. Figure
Fig. 7 G1XP lymphomas harbor a high level of clonal heterogeneity. a Quantification of c-myc translocations in G1XP lymphoma samples (n = 3
independent tumor samples) analyzed by metaphase FISH. We subdivide the configuration of FISH signals into three categories: Intact: green and
red probes co-localized; G only: green probe only (3′ c-myc), R only: red probe only (5′ c-myc). The frequency of different configurations of FISH
signals was shown from one representative sample, and at least 150 metaphases were analyzed in total for each sample. b Top: Diagram of c-myc
FISH probes. Bottom: Representative c-myc translocations showing different configurations of FISH signals. Numbers in parenthesis indicate the
number of FISH signals for each category. Intact: yellow arrows; G only: green arrows; R only: red arrows
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S2. G1XP lymphomas harbor somatic hypermutations. Germline se-
quences from either the JH1-4 or JH3-4 region were aligned with G1XP
lymphoma sequences. The mismatched sequences (in red font) at the
beginning of the sequences are derived from rearranged VD or D re-
gions. To exclude the effects of V(D)J recombination in sequence diver-
sity, we only identified the mutations in JH exon or intron regions that
could be unequivocally aligned to the germline sequences. The rear-
ranged JH exon regions are underlined for each individual G1XP lymph-
oma samples, and the mutations are marked with “*”. Figure S3. G1XP
lymphomas harbor normal or aberrant V(D)J recombination junctions.
NGS data showed the presence of normal D-J (junction 1) and V-D-J
(junction 2) junctions at the Igh locus or aberrant V-J junction (junction 3)
at Igλ locus.V, D, and J exons were labeled and depicted as orange
bars.MH: micro-homology. Figure S4.Clonal Igλtranslocations in G1XP
lymphoma. Top: schematics of Igλ locus on chromosome 16. Bottom:
Metaphases from G1XP lymphoma samples were analyzed by FISH for
hybridization to Igλ probes as indicated in the schematics. Representative
Igλ translocations in G1XP lymphomas are shown. Table S1. Phenotypic
characterization of G1XP lymphoma via flow cytometry. Table S2. Sum-
mary of translocation involved Igh and Igl genes. Table S3.Validation of
Translocations by PCR, Sanger Sequencing or FISH.(PDF 1221 kb)
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